drug_type
RELEVANT_DRUG
intervention_type
Autologous CAR T-cell therapy (cellular/gene therapy)
drug_description
Autologous T cells engineered ex vivo to express a claudin 18.2-specific CAR; after infusion they bind CLDN18.2 on tumor cells and trigger MHC-independent T-cell activation, cytokine release, and cytotoxic killing in CLDN18.2-positive gastric/GEJ adenocarcinoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a CAR that binds claudin 18.2; upon encountering CLDN18.2 on tumor cells, the CAR triggers MHC-independent T-cell activation, cytokine release, and cytotoxic killing of CLDN18.2-positive cancer cells.
drug_name
Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
nct_id_drug_ref
NCT06353152